Core Points - Lucid Diagnostics Inc. will host a conference call on September 8, 2025, at 8:30 AM ET to discuss the recent Contractor Advisory Committee meeting regarding the reconsideration of Local Coverage Determination for its EsoGuard® Esophageal DNA Test [1][2] - The EsoGuard® test is aimed at patients with GERD who are at risk of developing esophageal precancer and cancer, utilizing a noninvasive procedure for early detection [4] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on early detection of esophageal precancer in at-risk patients through its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device [4]

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [3] - The company focuses on patients with GERD (chronic heartburn) who are at risk of developing esophageal precancer and cancer [3]. Product Information - Lucid's flagship product is the EsoGuard® Esophageal DNA Test, which is performed using the EsoCheck® Esophageal Cell Collection Device [3]. - These tools are designed for the early detection of esophageal precancer in at-risk patients, aiming to prevent esophageal cancer and related deaths [3]. Upcoming Event - Lishan Aklog, M.D., Chairman and CEO of Lucid, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on September 5, 2025, at 8:35 AM EDT [1][2]. - The event will be available via live and archived webcast, accessible through the company's Investor Relations section [2].

Core Viewpoint - PAVmed Inc. has formed a new subsidiary to license advanced endoscopic imaging technology from Duke University, aimed at improving the diagnosis and treatment of esophageal dysplasia, which is a precursor to esophageal cancer [1][8]. Group 1: Technology and Collaboration - The technology involves a multi-modality probe that combines angle-resolved low coherence interferometry (a/LCI) with optical coherence tomography (OCT), potentially offering a more efficient alternative to traditional biopsies [1]. - PAVmed will collaborate with Lucid Diagnostics as a strategic and equity partner in this initiative [1]. - The technology is expected to enable real-time detection and immediate treatment of dysplasia during endoscopic procedures, addressing the limitations of traditional biopsy methods [3][6]. Group 2: Clinical Implications - Dr. Nicholas Shaheen highlighted that this technology could transform the diagnosis and treatment of esophageal precancer, improving patient outcomes and healthcare resource utilization [2]. - Prior clinical research indicated that the a/LCI technology demonstrated 100% sensitivity and 88% overall accuracy in detecting precancerous changes during live examinations [6]. - The integrated a/LCI and OCT technology has shown comparable sensitivity and improved specificity for detecting dysplasia, with results pending peer-reviewed publication [6]. Group 3: Company Strategy and Market Potential - PAVmed's CEO, Dr. Lishan Aklog, expressed optimism about the commercialization of this technology, anticipating that widespread adoption will significantly increase the diagnosis of esophageal precancer [7]. - The venture aligns with PAVmed's structure of independently financeable subsidiaries and builds on successful partnerships with academic medical centers [8]. - The exclusive worldwide license agreement for the a/LCI + OCT technology is contingent upon the execution of a definitive license agreement [8].

Lucid processed 2,756 EsoGuard® 2Q25 tests, recognized revenue of $1.2 million, and secured CAC meeting on Medicare LCD for EsoGuard to be held on September 4 Veris Health completed 2Q25 financing, relaunched development of implantable physiological monitor, and initiated integration steps to launch commercial phase with OSU-The James Conference call and webcast to be held today, August 14, at 8:30 AM EDT NEW YORK, Aug. 14, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diver ...

Core Insights - Lucid Diagnostics Inc. reported a revenue of $1.2 million for EsoGuard tests in Q2 2025, processing a total of 2,756 tests, and ended the quarter with over $30 million in proforma cash, extending its financial runway into 2026 [1][6][9] - A significant Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting regarding Medicare Local Coverage Determination (LCD) for EsoGuard is scheduled for September 4, 2025, which is seen as a critical step towards securing positive Medicare coverage [1][4][6] - The company has strengthened its balance sheet through a public offering, netting approximately $16.1 million in proceeds, and has initiated patient testing under a new commercial insurance coverage policy from Highmark Blue Cross Blue Shield [4][6][9] Business Highlights - The upcoming MolDx CAC meeting is viewed as a major milestone for Lucid, with expectations of strong support from medical experts for the clinical utility of EsoGuard [4] - Lucid has partnered with Hoag to launch a comprehensive EsoGuard testing program, enhancing access for at-risk patients [6] - A study sponsored by the National Cancer Institute (NCI) has shown that EsoGuard effectively detects esophageal precancer in patients without GERD symptoms, potentially increasing market opportunities by up to 70% [6] Financial Results - For the three months ended June 30, 2025, Lucid reported revenues of $1.2 million, with operating expenses of approximately $12.5 million, leading to a GAAP net loss of about $7.9 million or $(0.08) per share [9][10] - The non-GAAP adjusted loss for the same period was approximately $9.9 million or $(0.10) per share, reflecting the impact of stock-based compensation and other non-cash expenses [9][10] - Cash and cash equivalents stood at $31.1 million as of June 30, 2025, compared to $22.4 million at the end of 2024, indicating improved liquidity [9]

Company Overview - PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors [4] - The company has two subsidiaries: Lucid Diagnostics, which focuses on cancer prevention diagnostics, and Veris Health, which enhances personalized cancer care through remote patient monitoring [4] Upcoming Conference Call - PAVmed will host a business update conference call and webcast on August 14, 2025, at 8:30 AM ET [1] - The call will feature Lishan Aklog, M.D., the Chairman and CEO, providing an overview of the company's operations and growth strategy, along with Dennis McGrath, the President and CFO, discussing the second quarter 2025 financial results [1] Access Information - The webcast will be available on the investor relations section of the company's website [2] - U.S.-based callers can join the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2] Replay Availability - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [4]. Upcoming Conference Call - Lucid Diagnostics will host a business update conference call and webcast on August 13, 2025, at 8:30 AM ET [1]. - The call will feature Lishan Aklog, M.D., the Chairman and CEO, providing a business update and overview of the company's operations and growth strategy [1]. - Dennis McGrath, the CFO, will discuss the company's second quarter 2025 financial results during the call [1]. Access Information - The webcast will be available on the investor relations section of the company's website [2]. - U.S.-based callers can access the conference call by dialing 1-800-836-8184, while international listeners should dial 1-646-357-8785 [2]. - A replay of the conference call will be available for 30 days on the investor relations section of the company's website [3]. Product Information - Lucid's EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [4]. - The test is performed on samples collected using the EsoCheck® Esophageal Cell Collection Device, which involves a brief, noninvasive office procedure [4].

Group 1 - Lucid Diagnostics Inc. announced a virtual public meeting on September 4, 2025, to discuss the reconsideration of Local Coverage Determination (LCD) L39256 for its EsoGuard® Esophageal DNA Test [1] - The meeting will involve Medicare Administrative Contractors and medical experts, focusing on the clinical literature related to esophageal precancer testing [2] - Lucid's CEO expressed optimism about the meeting's potential to lead to a positive Medicare coverage policy outcome, citing broad consensus in the GI community regarding the clinical utility of EsoGuard [2] Group 2 - Lucid Diagnostics is a commercial-stage company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) at risk of esophageal precancer [3] - The EsoGuard® Esophageal DNA Test is designed for early detection of esophageal precancer through a noninvasive procedure, representing a significant advancement in cancer prevention tools [3]

Core Insights - PAVmed Inc. completed a private placement equity financing for its subsidiary Veris Health, raising $2.5 million at a pre-money valuation of approximately $35 million [1][2][3] Group 1: Financing Details - Veris Health sold shares at $1.40 per share, with proceeds aimed at advancing its implantable physiological monitor through FDA clearance expected in 2026 [2][3] - The financing follows a previous $2.4 million round completed earlier in the year, indicating ongoing investor interest and confidence in Veris Health's potential [1][2] Group 2: Product and Technology - Veris Health focuses on personalized cancer care through remote patient monitoring using implantable biologic sensors and connected external devices [2][4] - The Veris Cancer Care Platform integrates remote physiological data collection, symptom reporting, telehealth capabilities, and electronic health record integration to enhance patient care [4][5] Group 3: Strategic Importance - The financing is seen as a significant milestone for both PAVmed and Veris, providing necessary capital to fund the development and commercialization of the implantable physiological monitor [3][4] - The monitor is expected to serve as a key differentiator in the market, enhancing personalized care in conjunction with the Veris Cancer Care Platform [3][5]

Core Viewpoint - Lucid Diagnostics has partnered with Hoag to enhance access to EsoGuard esophageal precancer testing, aiming to combat the rising incidence of esophageal cancer in Orange County [1][2]. Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer [3]. - The EsoGuard® Esophageal DNA Test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients, performed through a non-invasive office procedure [3]. Partnership Details - Hoag has launched a comprehensive esophageal precancer testing program using Lucid's EsoGuard test, integrating it into its digestive health, primary care, and concierge medicine programs [1]. - The partnership is seen as a significant milestone in expanding access to EsoGuard within large healthcare systems, with expectations that it will serve as a model for other health systems [2]. Industry Context - The incidence of esophageal cancer has increased tenfold over the past four decades, highlighting the need for effective screening methods [2]. - The EsoGuard test offers a 3-minute non-endoscopic procedure aimed at identifying at-risk patients, which is critical for early intervention and potentially saving lives [2]. Hoag Overview - Hoag is a nonprofit regional healthcare delivery system in Orange County, California, recognized for its comprehensive personalized care and consisting of 1,800 physicians, 17 urgent care facilities, and two award-winning hospitals [5]. - It is ranked as the highest hospital in Orange County by U.S. News & World Report and is known for its specialized services in various health areas, including cancer and digestive health [5].